DNA-Based Immunotherapy IMNN-001 Promises to Improve Survival in Ovarian Cancer

New Data Confirms Darolutamide’s Safety and Efficacy in mHS Prostate Cancer

How AI Innovations Are Transforming Breast Cancer Screening

FDA Approves Sotorasib and Panitumumab Combo for KRAS G12C+ Colorectal Cancer

FDA Approves Innovative ADC Datroway for Metastatic HR+, HER2- Breast Cancer

Regulatory Approval Advances Pelareorep’s Virus Therapy for Pancreatic Cancer

FDA Approves 225Ac-SSO110 Radiopharmaceutical Trial for Small Cell Lung Cancer

FDA Grants Priority Review to Datopotamab Deruxtecan for EGFR+ Lung Cancer

The Internet of Medical Things needs a new security model to fulfil its potential

How AI Could Overcome Data Scarcity to Transform Medicine

First-Ever Obstructive Sleep Apnea Drug, Zepbound, Approved by FDA for Obesity

FDA Approves BRAFTOVI Combo as First-Line Treatment for Colorectal Cancer

The Recombinant Polyclonal Drug Candidate GIGA-2339 for Hepatitis B Treatment

How Qvin's Q-Pad Could Transform Women’s Health Through Menstrual Blood Testing

Palbociclib Combination Yields PFS Improvement in HR+, HER2+ Breast Cancer

AbbVie Acquires Nimble in $200 Million Deal to Strengthen Immunology Pipeline

Olaparib Shows Long-term Survival Benefits in BRCA+ and HER2- Breast Cancer

Imlunestrant Shows Promising Results Alone and with Verzenio in ER+, HER2- Breast Cancer

Elevation Partners with Synaffix in $368M Deal to Advance HER3 ADC Development

General Inception Acquires Enable Medicine to Drive AI-Led Drug Discovery

Ribociclib Shows Promising Long-Term Benefits in Early Breast Cancer Treatment

IL-15 Agonist NKTR-255 Enhances CAR-T Therapy Effectiveness in LB-Cell Lymphoma

FDA Grants Breakthrough Status to Datopotamab Deruxtecan for EGFR+ Lung Cancer

Breakthrough in First-Line Ovarian Cancer Treatment: KEYTRUDA and LYNPARZA

Blenrep Combination Reduces Death Risk by 42% in Relapsed Multiple Myeloma

Fixed-Duration Acalabrutinib Plus Venetoclax Achieves Superior 77% PFS in Untreated CLL

Adding Blinatumomab to Chemotherapy Extends 96% DF Survival in Pediatric Leukemia

Durvalumab Granted FDA Priority Review for Muscle-Invasive Bladder Cancer Patients

Promising Sac-TMT Receives FDA Breakthrough Therapy Designation for Lung Cancer

AI-Driven Cancer Therapy: Recursion Doses First Patient in REC-1245 Trial for Solid Tumors